{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:29:29Z","timestamp":1790803769918,"version":"4.1.0"},"reference-count":36,"publisher":"Pharmaceutical Society of Japan","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2020,4,1]]},"DOI":"10.1248\/bpb.b19-01091","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T22:04:09Z","timestamp":1580421849000},"page":"725-730","source":"Crossref","is-referenced-by-count":15,"title":["Azithromycin Inhibits Constitutive Airway Epithelial Sodium Channel Activation &lt;i&gt;in Vitro&lt;\/i&gt; and Modulates Downstream Pathogenesis &lt;i&gt;in Vivo&lt;\/i&gt;"],"prefix":"10.1248","volume":"43","author":[{"given":"Haruka","family":"Fujikawa","sequence":"first","affiliation":[{"name":"Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University"},{"name":"Program for Leading Graduate Schools \u201cHIGO (Health life science: Interdisciplinary and Glocal Oriented) Program,\u201d Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taise","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryunosuke","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoi","family":"Nasu","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Kamei","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University"},{"name":"Program for Leading Graduate Schools \u201cHIGO (Health life science: Interdisciplinary and Glocal Oriented) Program,\u201d Kumamoto University"},{"name":"Center for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Nohara","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University"},{"name":"Program for Leading Graduate Schools \u201cHIGO (Health life science: Interdisciplinary and Glocal Oriented) Program,\u201d Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Eto","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Ueno-Shuto","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology, Division of Life Science, Faculty of Pharmaceutical Sciences, Sojo University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Takeo","sequence":"additional","affiliation":[{"name":"Division of Reproductive Engineering, Center for Animal Resources and Development (CARD), Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Nakagata","sequence":"additional","affiliation":[{"name":"Division of Reproductive Engineering, Center for Animal Resources and Development (CARD), Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ann","family":"Suico","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University"},{"name":"Global Center for Natural Resources Sciences, Faculty of Life Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Kai","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University"},{"name":"Global Center for Natural Resources Sciences, Faculty of Life Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Shuto","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University"},{"name":"Global Center for Natural Resources Sciences, Faculty of Life Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Donaldson SH, Boucher RC. Sodium channels and cystic fibrosis. <i>Chest<\/i>, <b>132<\/b>, 1631\u20131636 (2007).","DOI":"10.1378\/chest.07-0288"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Canessa CM, Schild L, Buell G, Thorens B, Gautschi I, Horisberger J-D, Rossier BC. Amiloride-sensitive epithelial Na<sup>+<\/sup> channel is made of three homologous subunits. <i>Nature<\/i>, <b>367<\/b>, 463\u2013467 (1994).","DOI":"10.1038\/367463a0"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) \u00c5strand ABM, Hemmerling M, Root J, Wingren C, Pesic J, Johansson E, Garland AL, Ghosh A, Tarran R. Linking increased airway hydration, ciliary beating, and mucociliary clearance through ENaC inhibition. <i>Am. J. Physiol. Lung Cell. Mol. Physiol.<\/i>, <b>308<\/b>, L22\u2013L32 (2015).","DOI":"10.1152\/ajplung.00163.2014"},{"key":"4","unstructured":"4) Boucher RC. Cystic fibrosis: a disease of vulnerability to airway surface dehydration. <i>Trends Mol. Med.<\/i>, <b>13<\/b>, 231\u2013240 (2007)."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Zhao R, Liang X, Zhao M, Liu SL, Huang Y, Idell S, Li X, Ji HL. Correlation of apical fluid-regulating channel proteins with lung function in human COPD lungs. <i>PLOS ONE<\/i>, <b>9<\/b>, e109725 (2014).","DOI":"10.1371\/journal.pone.0109725"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Ghosh A, Boucher RC, Tarran R. Airway hydration and COPD. <i>Cell. Mol. Life Sci.<\/i>, <b>72<\/b>, 3637\u20133652 (2015).","DOI":"10.1007\/s00018-015-1946-7"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Shuto T, Kamei S, Nohara H, <i>et al<\/i>.  Pharmacological and genetic reappraisals of protease and oxidative stress pathways in a mouse model of obstructive lung diseases. <i>Sci. Rep.<\/i>, <b>6<\/b>, 39305 (2016).","DOI":"10.1038\/srep39305"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Mall M, Grubb BR, Harkema JR, O\u2019Neal WK, Boucher RC. Increased airway epithelial Na<sup>+<\/sup> absorption produces cystic fibrosis-like lung disease in mice. <i>Nat. Med.<\/i>, <b>10<\/b>, 487\u2013493 (2004).","DOI":"10.1038\/nm1028"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. <i>Int. J. Antimicrob. Agents<\/i>, <b>31<\/b>, 12\u201320 (2008).","DOI":"10.1016\/j.ijantimicag.2007.08.001"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Dinos GP. The macrolide antibiotic renaissance. <i>Br. J. Pharmacol.<\/i>, <b>174<\/b>, 2967\u20132983 (2017).","DOI":"10.1111\/bph.13936"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Desaki M, Takizawa H, Ohtoshi T, Kasama T, Kobayashi K, Sunazuka T, Omura S, Yamamoto K, Ito K. Erythromycin suppresses nuclear factor-\u03baB and activator protein-1 activation in human bronchial epithelial cells. <i>Biochem. Biophys. Res. Commun.<\/i>, <b>267<\/b>, 124\u2013128 (2000).","DOI":"10.1006\/bbrc.1999.1917"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Shimizu T, Shimizu S, Hattori R, Gabazza EC, Majima Y. <i>In vivo<\/i> and <i>in vitro<\/i> effects of macrolide antibiotics on mucus secretion in airway epithelial cells. <i>Am. J. Respir. Crit. Care Med.<\/i>, <b>168<\/b>, 581\u2013587 (2003).","DOI":"10.1164\/rccm.200212-1437OC"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Hirakata Y, Kaku M, Mizukane R, Ishida K, Furuya N, Matsumoto T, Tateda K, Yamaguchi K. Potential effects of erythromycin on host defense systems and virulence of Pseudomonas aeruginosa. <i>Antimicrob. Agents Chemother.<\/i>, <b>36<\/b>, 1922\u20131927 (1992).","DOI":"10.1128\/AAC.36.9.1922"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. <i>Am. J. Respir. Crit. Care Med.<\/i>, <b>157<\/b>, 1829\u20131832 (1998).","DOI":"10.1164\/ajrccm.157.6.9710075"},{"key":"15","unstructured":"15) Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, Milne D, Fergusson W, Tuffery C, Sexton P, Storey L, Ashton T. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. <i>Lancet<\/i>, <b>380<\/b>, 660\u2013667 (2012)."},{"key":"16","unstructured":"16) Albert RK, Connett J, Bailey WC, <i>et al.<\/i> Azithromycin for prevention of exacerbations of COPD. <i>N. Engl. J. Med.<\/i>, <b>365<\/b>, 689\u2013698 (2011)."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Jaff\u00e9 A, Francis J, Rosenthal M, Bush A. Long-term azithromycin may improve lung function in children with cystic fibrosis. <i>Lancet<\/i>, <b>351<\/b>, 420 (1998).","DOI":"10.1016\/S0140-6736(05)78360-4"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Caldwell RA, Boucher RC, Stutts MJ. Neutrophil elastase activates near-silent epithelial Na<sup>+<\/sup> channels and increases airway epithelial Na<sup>+<\/sup> transport. <i>Am. J. Physiol. Lung Cell. Mol. Physiol.<\/i>, <b>288<\/b>, L813\u2013L819 (2005).","DOI":"10.1152\/ajplung.00435.2004"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Bhalla V, Hallows KR. Mechanisms of ENaC regulation and clinical implications. <i>J. Am. Soc. Nephrol.<\/i>, <b>19<\/b>, 1845\u20131854 (2008).","DOI":"10.1681\/ASN.2008020225"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Tarran R, Sabater JR, Clarke TC, Tan CD, Davies CM, Liu J, Yeung A, Garland AL, Stutts MJ, Abraham WM, Phillips G, Baker WR, Wright CD, Wilbert S. Nonantibiotic macrolides prevent human neutrophil elastase-induced mucus stasis and airway surface liquid volume depletion. <i>Am. J. Physiol. Lung Cell. Mol. Physiol.<\/i>, <b>304<\/b>, L746\u2013L756 (2013).","DOI":"10.1152\/ajplung.00292.2012"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Kamei S, Fujikawa H, Nohara H, Ueno-Shuto K, Maruta K, Nakashima R, Kawakami T, Matsumoto C, Sakaguchi Y, Ono T, Suico MA, Boucher RC, Gruenert DC, Takeo T, Nakagata N, Li JD, Kai H, Shuto T. Zinc deficiency <i>via<\/i> a splice switch in zinc importer ZIP2\/SLC39A2 causes cystic fibrosis-associated MUC5AC hypersecretion in airway epithelial cells. <i>EBioMedicine<\/i>, <b>27<\/b>, 304\u2013316 (2018).","DOI":"10.1016\/j.ebiom.2017.12.025"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Sugahara T, Koga T, Ueno-Shuto K, Shuto T, Watanabe E, Maekawa A, Kitamura K, Tomita K, Mizuno A, Sato T, Suico MA, Kai H. Calreticulin positively regulates the expression and function of epithelial sodium channel. <i>Exp. Cell Res.<\/i>, <b>315<\/b>, 3294\u20133300 (2009).","DOI":"10.1016\/j.yexcr.2009.09.023"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Takeo T, Nakagata N. Superovulation using the combined administration of inhibin antiserum and equine chorionic gonadotropin increases the number of ovulated oocytes in C57BL\/6 female mice. <i>PLOS ONE<\/i>, <b>10<\/b>, e0128330 (2015).","DOI":"10.1371\/journal.pone.0128330"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Nakashima R, Kamei S, Nohara H, Fujikawa H, Maruta K, Kawakami T, Eto Y, Takahashi N, Suico MA, Takeo T, Nakagata N, Kai H, Shuto T. Auto-measure emphysematous parameters and pathophysiological gene expression profiles in experimental mouse models of acute and chronic obstructive pulmonary diseases. <i>J. Pharmacol. Sci.<\/i>, <b>140<\/b>, 113\u2013119 (2019).","DOI":"10.1016\/j.jphs.2019.01.011"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Button B, Cai LH, Ehre C, Kesimer M, Hill DB, Sheehan JK, Boucher RC, Rubinstein M. A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia. <i>Science<\/i>, <b>337<\/b>, 937\u2013941 (2012).","DOI":"10.1126\/science.1223012"},{"key":"26","unstructured":"26) Zhou-Suckow Z, Duerr J, Hagner M, Agrawal R, Mall MA. Airway mucus, inflammation and remodeling: emerging links in the pathogenesis of chronic lung diseases. <i>Cell Tissue Res.<\/i>, <b>367<\/b>, 537\u2013550 (2017)."},{"key":"27","unstructured":"27) Cameron EJ, Mcsharry C, Chaudhuri R, Farrow S, Thomson NC. Long-term macrolide treatment of chronic inflammatory airway diseases: Risks, benefits, and future developments. <i>Clin. Exp. Allergy<\/i>, <b>42<\/b>, 1302\u20131312 (2012)."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Kasetty G, Bhongir RKV, Papareddy P, Herwald H, Egesten A. The nonantibiotic macrolide em703 improves survival in a model of quinolone-treated pseudomonas aeruginosa airway infection. <i>Antimicrob. Agents Chemother.<\/i>, <b>61<\/b>, e02761\u201316 (2017).","DOI":"10.1128\/AAC.02761-16"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Sugawara A, Sueki A, Hirose T, Shima H, Akagawa KS, \u014cmura S, Sunazuka T. Novel 12-membered non-antibiotic macrolides, EM900 series with anti-inflammatory and\/or immunomodulatory activity; Synthesis, structure\u2013activity relationships and <i>in vivo<\/i> study. <i>J. Antibiot.<\/i>, <b>65<\/b>, 487\u2013490 (2012).","DOI":"10.1038\/ja.2012.51"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Mencarelli A, Distrutti E, Renga B, Cipriani S, Palladino G, Booth C, Tudor G, Guse JH, Hahn U, Burnet M, Fiorucci S. Development of non-antibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatory bowel diseases and arthritis. <i>Eur. J. Pharmacol.<\/i>, <b>665<\/b>, 29\u201339 (2011).","DOI":"10.1016\/j.ejphar.2011.04.036"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Zhou Z, Treis D, Schubert SC, Harm M, Schatterny J, Hirtz S, Duerr J, Boucher RC, Mall MA. Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in \u03b2ENaC-overexpressing mice. <i>Am. J. Respir. Crit. Care Med.<\/i>, <b>178<\/b>, 1245\u20131256 (2008).","DOI":"10.1164\/rccm.200803-442OC"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Scott DW, Walker MP, Sesma J, Wu B, Stuhlmiller TJ, Sabater JR, Abraham WM, Crowder TM, Christensen DJ, Tarran R. SPX-101 is a novel epithelial sodium channel\u2013targeted therapeutic for cystic fibrosis that restores mucus transport. <i>Am. J. Respir. Crit. Care Med.<\/i>, <b>196<\/b>, 734\u2013744 (2017).","DOI":"10.1164\/rccm.201612-2445OC"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Couroux P, Farias P, Rizvi L, Griffin K, Hudson C, Crowder T, Tarran R, Tullis E. First clinical trials of novel ENaC targeting therapy, SPX-101, in healthy volunteers and adults with cystic fibrosis. <i>Pulm. Pharmacol. Ther.<\/i>, <b>58<\/b>, 101819 (2019).","DOI":"10.1016\/j.pupt.2019.101819"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Crosby JR, Zhao C, Jiang C, Bai D, Katz M, Greenlee S, Kawabe H, McCaleb M, Rotin D, Guo S, Monia BP. Inhaled ENaC antisense oligonucleotide ameliorates cystic fibrosis-like lung disease in mice. <i>J. Cyst. Fibros.<\/i>, <b>16<\/b>, 671\u2013680 (2017).","DOI":"10.1016\/j.jcf.2017.05.003"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Azoulay-Dupuis E, Vallee E, Bedos JP, Muffat-Joly M, Pocidalo JJ. Prophylactic and therapeutic activities of azithromycin in a mouse model of pneumococcal pneumonia. <i>Antimicrob. Agents Chemother.<\/i>, <b>35<\/b>, 1024\u20131028 (1991).","DOI":"10.1128\/AAC.35.6.1024"},{"key":"36","unstructured":"36) Uzun S, Djamin RS, Kluytmans JAJW, Mulder PGH, van\u2019t Veer NE, Ermens AAM, Pelle AJ, Hoogsteden HC, Aerts JGJV, Van der Eerden MM. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. <i>Lancet Respir. Med.<\/i>, <b>2<\/b>, 361\u2013368 (2014)."}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/43\/4\/43_b19-01091\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T03:22:30Z","timestamp":1585970550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/43\/4\/43_b19-01091\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b19-01091","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,1]]}}}